   Program Organisers Abstracts Participants |
2007
København, Denmark
| Balaji Agoram, Steven Martin, Piet van der Graaf. Application of mechanism-based population PKPD modelling in the rational selection of clinical candidates: an anti-IgE antibody example. |
| S. Albers (1), B. Meibohm (2), J. Barrett (3), TS. Mir (4), S. Laer (1) Population Pharmacokinetics and Dose Simulation of Carvedilol in Pediatric Patients with Congestive Heart Failure |
| Aldaz A. (1), Sayar O. (1), Zufia L.(1), Viudez A.(2), Rifon J.(3), Nieto Y.(4) Comparison between NONMEM and NPAG for gemcitabine modelling |
| Sayar O.(1), Aldaz A. (1),Zufia L.(1), Viudez A.(2), Rifón J.(3), Nieto Y.(4) New model for gemcitabine and its metabolites |
| L. Alifrangis (1), P. André (2), R.V. Overgaard (1), C. Sola (2), A. Tisserant (2), N. Wagtmann (1), F. Romagne (2), S.H. Ingwersen (1). Setting a Safe Starting Dose for a First-in-Man trial of a Monoclonal Antibody Based on Population PK-PD Predictions |
| Antic, Julie (1,2) ; Chafaï, Djalil (1) ; Laffont, Céline (2) ; Concordet, Didier (1) Evaluation of Non Parametric Methods for population PK/PD |
| J. Areberg, L.E. Broksø Kyhl Simultaneous Population Pharmacokinetic Modelling of Parent Compound and Metabolite in Plasma and Urine for a New Drug Candidate |
| Jeffrey S. Barrett, Jeffrey Skolnik, Bhuvana Jayaraman, Dimple Patel, Peter Adamson Improving Study Design and Conduct Efficiency of Event-Driven Clinical Trials via Discrete Event Simulation: Application to Pediatric Oncology |
| Robert J. Bauer Advanced Population Analysis Features in the S-ADAPT/MCPEM Program |
| Paul G Baverel, Radojka M Savic, Justin J Wilkins, Mats O Karlsson, Evaluation Of The Nonparametric Estimation Method In NONMEM VI: Application To Real Data |
| C. Bazzoli (1), S. Retout (1, 2), F. Mentré (1, 2) Population design in nonlinear mixed effects multiple responses models: extension of PFIM and evaluation by simulation with NONMEM and MONOLIX |
| Neil Benson1, Nelleke Snelder2, Bart Ploeger2 , Carolyn Napier1, Harriet Sale1 and Piet van der Graaf1 Utility of a mixed effects approach to defining target binding rate constants. |
| Martin Bergstrand, Elodie Plan, Maria Kjellsson, Mats O Karlsson A comparison of methods for handling of data below the limit of quantification in NONMEM VI |
| J. Bertrand (1), X. Panhard (1), A. Tran (2), E. Rey (2), S. Auleley (1), X. Duval (1, 3, 5), D. Salmon (4), J.M. Tréluyer (2), F. Mentré (1) and the COPHAR2- ANRS 111 study group Influence of pharmacogenetic on pharmacokinetic interindividual variability of indinavir and lopinavir in HIV patients (COPHAR2 – ANRS 111 trial) |
| Robert R. Bies1, Serge Guzy2, Joshua Sokoloski3, Laura Drewencki3, and Amy K. Wagner3. An MCPEM approach to understanding inter-animal and inter-treatment changes with in vivo striatal dopamine clearance in rats. |
| Emma Boström, Margareta Hammarlund-Udenaes and Ulrika SH Simonsson Blood-brain barrier transport helps explain discrepancies in in vivo potency between oxycodone and morphine |
| Brendel K1,2, Comets E1, Laffont C.M2, Mentré F1,3. Normalized Prediction Distribution Error for the Evaluation of Nonlinear Mixed-Models |
| Vincent Buchheit, Marie-Odile Lemarechal, Caterina Ferioli, Aurelie Gautier, Gregory Pinault, Kathy Chen*, Goonaseelan (Colin) Pillai, Jean-Louis Steimer A dedicated SAS Programming Group working in a pharmaceutical Modeling & Simulation organization - Current role, experience and prospects |
| Clare Gaynor (1), Adrian Dunne (1) and John Davis (2) An assessment of prediction accuracy of two IVIVC modelling methodologies. |
| Marc Buyse Validation of statistically reliable biomarkers |
| Callies Sophie, Andre Valerie, Vick Andrew-Mark, Graff Jeremy, Patel Bharvin, Brail Leslie, Lahn Michael Modelling pharmacokinetic and pharmacodynamic properties of second generation antisense-oligonucleotides (ASOs). |
| Massimo Cella(1), Gijs Santen(1), Frederik Gorter de Vries(1),Meindert Danhof(1), Oscar Della Pasqua(1,2) A model-based approach to dose selection in early paediatric development |
| Marylore Chenel1, Kayode Ogungbenro2, François Bouzom1 Comparison of uniresponse and multiresponse approaches of PopDes to optimize sampling times for drug-drug interaction studies: application to a Servier compound. |
| Sau Yan Amy Cheung (1), James W. T. Yates (2), Oneeb Majid (3), Leon Aarons (4) Identifiability Analysis and Parameter List Reduction of a Nonlinear Cardiovascular PKPD Model |
| Yumi Fukushima (1), Jean-Eric Charoin (1), Michael Brewster (2), E. Niclas Jonsson (1) Population Pharmacokinetic Analysis of Trastuzumab (Herceptin®) based on Data from Three Different Dosing Regimens. |
| Claudio Cobelli Models of Glucose Metabolism and Control in Diabetes |
| Emmanuelle Comets (1), Karl Brendel (2) and France Mentré (1,3) Normalised prediction distribution errors in R: the npde library |
| Didier Concordet, Djalil Chafaï How to estimate population variance matrices with a Prescribed Pattern of Zeros? |
| C.Crepin(1), E.Fuseau(1), M.Portugal(2), D.Humilier(2) Elimination of anti-epileptic compounds in Marseille aquatic environment from private hospital effluent - modelling versus measurements |
| C. Dansirikul, M.O. Karlsson Insulin secretion and hepatic extraction during euglycemic clamp study: modelling of insulin and C-peptide data |
| Dartois C, Looby M, He H, Steimer J-L, and Pillai G. Impact of handling missing PK data on PD estimation – explicit modeling of BLQ data in WinBUGS® reduced bias in the PD predictions - a preclinical example. |
| X Delavenne (1), T Basset (2), P Girard (3) , H Decousus (1,4), P Mismetti (1,4), S Laporte (1) The use of an indirect response model to assess interaction between drugs: acenocoumarol and amoxicillin + clavulanic acid |
| Dickinson GL (1), Dawson M (2), Ward TH (2), Danson S (3), Ranson M (2), Dive C (2), Aarons L (1). Population pharmacokinetics of a novel anticancer drug, RH1, in terminal cancer patients. |
| Aris Dokoumetzidis An algorithm for proper lumping of systems of ODEs |
| Mike Dunlavey Next-Generation Modeling Language |
| Jeroen Schaap (1), Stefan Verhoeven (2), Gerard Vogel (3), Martijn Rooseboom (3,4) and Rene van Schaik (2) Automation of Structural Pharmacokinetic Model Search in NONMEM: Evaluation with Preclinical Datasets |
| Jeroen Schaap Interspecies Population Modeling Of Pharmacokinetic Data Available At The End Of Drug Discovery |
| D J Eleveld (1), J K G Wietasch (2), J H Proost (1), S Guzy(3), A Hoeft (4) Is the expected performance of a target-controlled-infusion system influenced by the population analysis method |
| M.A. Fabre (2), E. Fuseau (2), A. Vermeulen (1), A. Thyssen (1). Population pharmacokinetic analysis in children, adolescents and adults with schizophrenia or bipolar disorder |
| M.A. Fabre (2), E. Fuseau (2), P. Cohen, H. Ficheux (1). Selection of a dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modelling. |
| Marc-Antoine Fabre, Eliane Fuseau(1), Maria-Laura Sargentini-Maier, Nathalie Toublanc(2) Retrospective population pharmacokinetic analysis of seletracetam in epileptic and healthy adults |
| Frederique Fenneteau, Jun Li, Jacques Turgeon, Fahima Nekka A Physiologically Based Pharmacokinetic Model to Assess the Role of ABC Transporters in Drug Distribution |
| Fernandez-Teruel Carlos (1), Gonzalez-Alvarez Isabel (2), Navarro-Fontestad Carmen (2), Nalda-Molina Ricardo (3), Garcia-Arieta Alfredo (4), Bermejo-Sanz Marival (2), Casabo-Alos Vicente (2). Simulations of bioequivalence trials using physiological-pharmacokinetic models with saturable and non-saturable hepatic clearance |
| Francesca Del Bene, Massimiliano Germani, Maurizio Rocchetti, Alex De Giorgio-Miller, Nick Pullen, Peter Bungay, Chris Kohl & Piet van der Graaf A population PK-PD method for categorical data analysis of progesterone antagonist activity in the rabbit McPhail’s model |
| Gibiansky E. (1), J. Janik (2), D. Mahony (2), K. Kaucic (1), L. Hammershaimb (1), G. Robbie (1). Population Pharmacokinetics of Siplizumab (MEDI-507): Implications for Dosing |
| Leonid Gibiansky Precision of Parameter Estimates: Covariance Step ($COV) versus Bootstrap Procedure |
| Ihab G. Girgis, Tom Schaible, Partha Nandy, Filip De Ridder, Jeffrey Mathers, and Surya Mohanty Parallel Bayesian Methodology for Population Analysis |
| Ihab G. Girgis, Vivek Viswanathan, Partha Nandy, and Surya Mohanty Interactive Graphical Visualization Tool for Safety Data Screening |
| I. Grabnar(1), B. Faganel(2), V. Dolzan(3), A. Mrhar(1), J. Jazbec(2) Population Pharmacokinetics of Methotrexate in Children with Lymphoid Malignancy |
| Thaddeus Grasela, PharmD, PhD The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process |
| J. Grevel1, E. Fuseau1, C. Crepin1, M. Vernaz-Gris1, M. Marchand1, D. Huntjens2 Evaluation of the population pharmacokinetic properties of lidocaine and its metabolites, MEGX, GX, and 2,6-xylidine, after application of lidocaine 5% medicated plaster. |
| Andreas Groth1, Judi Møss2, Tine Møller3, Steen Ingwersen1 A Population PK/PD Model Assessing The Pharmacodynamics Of A Rapid-Acting Recombinant FVII Analogue, NN1731, In Healthy Male Subjects |
| Ivelina Gueorguieva and Kimberley Jackson Prospective application of a multivariate population optimal design to determine parent and metabolite pharmacokinetic sampling times in a Phase II study. |
| Serge Guzy Combining interoccasion variability and mixture within a MCPEM framework |
| Robert Bauer(1), Serge Guzy(1), Hanna E Silber(2), Petra M Jauslin(2,3), Nicolas Frey(3), Mats O Karlsson(2) Comparison between NONMEM and the Monte-Carlo Expectation Maximization (MC-PEM) Method Using a Physiologically-Based Glucose-Insulin Model |
| E.K. Hansson(1), M. Sandström(2), H. Lindman(3), L.E. Friberg(1) Modelling of Chemotherapy-induced Febrile Neutropenia using the Predicted Degree and Duration of Myelosuppression |
| Emilie Hénin (1,2), Véronique Trillet-Lenoir (1,2,3), Olivier Colomban (1,2), Michel Tod (1,2), Pascal Girard (1,2) Estimation of patient compliance from pharmacokinetic samples |
| S. Hennig(1), R. Norris(2) C. M. J. Kirkpatrick(1) Tobramycin in paediatric CF patients - TCI or “One dose fits all” |
| D. Hirt, F. Batteux, S. Urien, J.P. Richardet, P. Sogni, J. Poupon, A. Laurent, S. Pavlovic, M. Debray, J.M. Treluyer, B. Weill Pharmacokinetic-pharmacodynamic modeling of manganese in patients with acute alcoholic hepatitis after an IV infusion of mangafodipir. |
| D. Hirt, F. Mentré, A. Tran, E. Rey, S. Auleley, X. Duval, D. Salmon, J.M. Tréluyer, and the COPHAR2- ANRS study group. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. |
| Almond L1, Rowland Yeo K1, Howgate EM1, Tucker GT1,2, Rostami-Hodjegan A1,2 Mechanistic Prediction of HIV Drug-Drug Interactions in Virtual Populations from in vitro Enzyme Kinetic Data: Ritonavir and Saquinavir. |
| Pankaj Gupta, Matthew M Hutmacher, Bill Frame and Raymond Miller A new approach for population pharmacokinetic data analysis under noncompliance |
| Bojan Lalovic, Matthew M Hutmacher, Bill Frame, Kaori Ito, Raymond Miller Modeling the Dropout from Longitudinal Adverse Event Data: Selecting Optimal Titration Regimens |
| Matthew M Hutmacher, Anand Vidyashankar, Debu Mukherhjee Comparing Minimum Hellinger Distance Estimation (MHDE) and Hypothesis Testing to Traditional Statistical Analyses – a Simulation Study |
| L. Iavarone(1), R. Gomeni(1), E. Merlo-Pich(2) Population PK/PD of Alprazolam in the Attenuation of ACTH Activation Induced by Cognitive Performance in Metyrapone-treated Healthy Volunteers |
| Philippe Jacqmin (1), Lynn McFadyen (2) and Janet R. Wade (1) Basic PK/PD principles of proliferative and circular systems |
| Andrea Kwa, Pharm.D1, Juraj Sprung, M.D., Ph.D.2, Michael Van Guilder, Ph.D3., Roger W. Jelliffe, M.D.3 A Population Model of Epidural Lidocaine |
| R Jelliffe, A Schumitzky, D Bayard, R Leary, M Van Guilder, A Gandhi, M Neely, and A Bustad. The USC*PACK collection of BigWinPops software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software |
| P. Johnson (1), H. Dai (2), S. Neelakantan (2), T. Tensfeldt (2) Optimal dose & sample-size selection for dose-response studies |
| Daniël M. Jonker, Estelle Watson, Anders Dyhr Toft, Peter Kristensen, Lotte Bjerre Knudsen, Steen H. Ingwersen Pharmacokinetic modelling of the once-daily human glucagon-like peptide-1 analogue, liraglutide, in healthy volunteers and comparison to exenatide |
| Kristin E. Karlsson(1), Justin Wilkins(1,3), Mats O. Karlsson(1) and E. Niclas Jonsson(1,2) Modelling of disease progression in acute stroke by simultaneously using the NIH stroke scale, the Scandinavian stroke scale and the Barthel index |
| RJ Keizer(1), E van Twuijver(2), JJ Marcar(2), PFW Strengers(2), ADR Huitema(1) Bioequivalence study of a C1-esterase-inhibitor product (Cetor®) with optimised sampling design |
| Hui Kimko, Steven Xu, Bindu Murthy, Mahesh Samtani, Partha Nandy, Richard Strauss, Gary Noel Population Pharmacokinetic Analysis To Support Dosing Regimens Of Ceftobiprole |
| Maria C. Kjellsson (1), Daniele Ouellet (2), Raymond Miller (2), Mats O. Karlsson (1) Modelling Sleep Using Markov Mixed Effects Models |
| T Klitgaard , JN Nielsen, MS Fitsios, and M Lange Population Pharmacokinetic Model for Human Growth Hormone in Adult Patients in Chronic Dialysis vs. Healthy Subjects |
| Kevin M. Krudys, Oscar Della-Pasqua Can Bayes Prevent QTC-interval prolongation? A challenge beyond random effects. |
| Wojciech Krzyzanski (1) and Juan Jose Perez Ruixo (2) Pharmacodynamic Modelling of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects |
| K. Kuester(1,3), A. Kovar(2), B. Brockhaus(2), C. Kloft(1,3) Matuzumab – A Population Pharmacokinetic Model and its Evaluation |
| Laffont CM (1), Mentré F (2) and Foos-Gilbert E (1) Population pharmacokinetic analysis of perindoprilat in hypertensive paediatric patients |
| Lemenuel-Diot A., Laffont C.M. , Jochemsen R., Foos-Gilbert E. Evaluation of model of Heart Rate during Exercise Tolerance Test with missing at random dropouts |
| PLS Chan, E van Schaick, G Langdon, J Davis, T Parkinson, L McFadyen PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor |
| F. Larsen (1), C. Bundgaard (2) Non-Linear Mixed Effects PK/PD Modelling of Acute Autoinhibitory Feedback Effects of Escitalopram (ESC) on Extracellular Serotonin (5-HT) Levels in Rat Brain |
| M. Lavielle (1,2), H. Mesa (3,2), F. Mentré (4,5) The SAEM algorithm and its implementation in MONOLIX 2.1 |
| Robert H. Leary An evolutonary nonparametric NLME algorithm |
| R. Lledó-García (1), M. Merino Sanjuán (1), L. Prats (1), A. Nácher (1), V.G. Casabó (1) Population Pharmacokinetics of Saquinavir in rats after IV and IP administration. An approach to Saquinavir/Ritonavir Pharmacokinetic interaction. |
| Viera Lukacova, Walter S. Woltosz, Michael B. Bolger PK/PD modeling of Adinazolam – effect of variability of absorption, PK and PD parameters on variability in PD response |
| Mathilde Marchand (1, 2), Eliane Fuseau (1), David Critchley (3) Supporting the recommended paediatric dosing regimen for rufinamide using clinical trial simulation |
| Mathilde Marchand (1, 2), Eliane Fuseau (1) Predicting human from animal PBPK simulation combined with in vitro data |
| M. Marchand (1), E. Fuseau (1), A.C. Heatherington (2), S. Sultana (2), P. R. Hidi (2), M. Boucher (2), P. Ellis (2), S.W. Martin (2) Population PKPD modelling of biomarkers ANP and big ET-1 for two neutral endopeptidase inhibitors |
| Jean-Marie MARTINEZ, David FABRE & Vanaja KANAMALURU Population Pharmacokinetics of Rimonabant in Obesity |
| Matthews, I and Aarons, L Sensitivity analysis of a mixture model to determine genotype/phenotype |
| L. McFadyen (1), P. Jacqmin (2), J. Wade (2), B. Weatherley (1) Maraviroc Exposure Response Analysis: Phase 3 Antiviral Efficacy in Treatment Experienced HIV+ Patients |
| Divya Menon (1), John T. Mondick (1), Bhuvana Jayaraman (1), Albert T. Cheung (2), Jeffrey S. Barrett (1) Pharmacokinetics / Pharmacodynamics of Intravenous Bolus Nicardipine in Adults Undergoing Cardiovascular Surgery |
| F. Mentré (1), S. Duffull (2), I. Gueorguieva (3), A. Hooker (4), S. Leonov (5), K. Ogungbenro (6), S. Retout (1) Software for optimal design in population pharmacokinetics and pharmacodynamics: a comparison |
| Ricardo Nalda-Molina1, Belén Valenzuela(1), Arturo Soto-Matos(2), Bernardo Miguel-Lillo(2), Miguel Angel Izquierdo(2) Population Pharmacokinetics of Aplidin® (plitidepsin) in Subjects with Cancer |
| Ramón-López A. (1), Nalda-Molina R. (1), Valenzuela B. (1), Pérez Ruixo J.J.(2) Semi-mechanistic PKPD model for neutropenia using K-PD model in patients receiving high dose of chemotherapy |
| Michael Neely (1), Natella Rakhmanina (2), John Van Den Anker (2), Steven Soldin (2), Mike Van Guilder (1), Alan Schumitzky (1), Roger Jelliffe (1) Impact of Lopinavir Limit of Quantification (LOQ)-Censored Data Replacement on Population Pharmacokinetic (PK) Plasma and Saliva Modeling in HIV-Infected Children |
| F. Nekka, J. Li and F. Fenneteau What Additional Information Can we Retrieve When Compliance is Accounted For? An explicit Compliance-Pharmacokinetic Formalism |
| A. Russu (1), M. Neve (2), G. De Nicolao (1), I. Poggesi (2), R. Gomeni (2) Population methods for dose escalation studies: an MCMC approach |
| Ng CM (1), Bauer RJ (2), Beeram M (1), Takimoto CH (1), Lin C (1), Patnaik A (1) A Systematical Approach to Bridge the Two-Stage Parametric Expectation Maximization Algorithm and Full Bayesian Three-Stage Hierarchical Nonlinear Mixed Effect Methods in Complex Population Pharmacokinetic/Pharmacodynamic Analysis: Troxacitabine-induced Neutropenia in Cancer Patients |
| RJ Bauer (1), S Guzy (1), CM Ng (2) A Comparison of Estimation Methods in Nonlinear Mixed-effect Model for Population Pharmacokinetic-pharmacodynamic Analysis |
| Bizzotto R, Nucci G, Poggesi I, Gomeni R A Bayesian approach for the integration of preclinical information into a PBPK model for predicting human pharmacokinetics |
| Gianluca Nucci, Keith Muir and Roberto Gomeni Population pharmacokinetic modelling of pimozide and its relation to CYP2D6 genotype. |
| Joakim Nyberg, Mats O Karlsson, Andrew Hooker Sequential versus simultaneous optimal experimental design on dose and sample times |
| Kayode Ogungbenro and Leon Aarons Sample Size Calculations for Repeated Binary Population Pharmacodynamic Experiments |
| Olofsen, E The performance of model selection criteria in the absence of a fixed-dimensional correct model |
| M.C. Peterson(1), M.M. Riggs(2) Calcium Homeostasis and Bone Remodeling: Development of an Integrated Model for Evaluation and Simulation of Therapeutic Responses to Bone-Related Therapies |
| K. Petersson, E. Hanze, R.M. Savic, M.O. Karlsson Semiparametric distributions with estimated shape parameters: Implementation and Evaluation |
| Marcella Petrone, Stefano Zamuner, Vincenzo Di Iorio, Roger Gunn, Marc Laruelle and Roberto Gomeni Model-based sequential human PET study design for Optimal PK/RO assessment |
| Zexun Zhou, Marc Pfister, and Amit Roy Optimal Sampling Design and Trial Simulation using POPT and NONMEM |
| E. Plan, M. C. Kjellsson, M. O. Karlsson Investigation of performances of FOCE and LAPLACE algorithms in NONMEM VI in population parameters estimation of PK and PD continuous data |
| Teun Post(1), Tomoo Funaki(2), Hiromi Maune(2), Henk-Jan Drenth(1) Circadian rhythm in pharmacodynamics and its influence on the identification of treatment effects |
| R.R. Press(1), B.A. Ploeger(2,3), J. den Hartigh(1), R.J.H.M. van der Straaten(1), J. van Pelt(1), M.Danhof(2,3), J.H. de Fijter(1), H.J. Guchelaar(1). Dose prediction of tacrolimus in de novo kidney transplant patients with population pharmacokinetic modelling. |
| N.H. Prins(1), G. Graham(2), C. Muto(3), A. Pidgen(4) Modeling of plasma aldosterone concentrations after prokinetic 5-HT4 receptor agonists: forming an integrated simulation framework for summary statistic and subject-level data. |
| E.H. Cox (1)(3), N.H. Prins (1), G. D’Souza (2) & L. McFadyen (2) Integrated Modeling & Simulation of Clinical Response and Drop-out of D2 receptor agonists in Patients with Early Parkinson’s Disease. |
| Dittberner, S. (1), V. Duval (2), A. Staab (2), I. Troconiz (3), U. Graefe-Mody (2), U. Jaehde (1) Determination of the absolute bioavailability of BI 1356, a substance with non-linear pharmacokinetics, using a population pharmacokinetic modelling approach |
| S. Retout (1, 2), C. Bazzoli (1), E. Comets (1), H. Le Nagard (1), F. Mentré (1, 2) Population designs evaluation and optimisation in R: the PFIM function and its new features |
| Ribba B., Tod M., Girard P., You B., Mercier C., Vassal G., Freyer G., Tranchand B. ODE solvers and stiffness issues for complex population PK models |
| Stefaan Rossenu (1), Clare Gaynor (2), An Vermeulen (1), Adrian Dunne (2) and Adriaan Cleton (1) A mixture distribution approach to IVIVC modeling of a dual component drug delivery system |
| David Salinger and the Resource Facility for Population Kinetics (RFPK) The System for Population Kinetics (SPK) |
| Mahesh N. Samtani, Juan Jose Perez-Ruixo, Kathryn Brown, Dirk Cerneus, Christopher Molloy PK/PD Model of Pegylated Thrombopoietin Mimetic Peptide in Healthy Subjects: Comparison of Verification Procedures for Assessing Model Predictability. |
| Gijs Santen(1), Meindert Danhof(1), Oscar Della Pasqua(1,2) Comparing treatment effect in depression trials: Mixed Model for Repeated Measures vs Linear Mixed Model |
| Radojka M. Savic and Mats O. Karlsson Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics and Estimation: Problems and Solutions |
| Tim Sheiner Planning To Communicate |
| C.M.T. Sherwin (1, 2), S. Svahn (3), A.J. Van Der Linden (4), N.J. Medlicott (2), R. Broadbent (1), D.M. Reith (1) A pharmacokinetic/pharmacodynamic model to determine optimal dosing targets for amikacin in neonatal sepsis |
| Soy D1, Clopés A2, Farré R3, Mangues MA3 Population Pharmacokinetic Modeling Of Busulfan In Patients Undergoing Autologous Stem Cell Transplantation (ASCT) For Multiple Myeloma |
| K.H. Liesenfeld, J. Stangier, H.G. Schaefer, A. Staab How can routinely collected comedication information from phase II/III trials be used for screening of potential effects on model parameters? A case study with the oral direct thrombin inhibitor Dabigatran etexilate |
| JF Standing (1,2), RF Howard (1,3), A Johnston (4), I Savage (2), ICK Wong (1,2,3) Developmental Pharmacokinetics of Diclofenac for Acute Pain |
| Christian Laveille(1), Eric Snoeck(1), Brigitte Lacroix(2), Maria Laura Sargentini-Maier(2), Armel Stockis(2) Dose-response population modeling of the new antiepileptic drug brivaracetam in add-on treatment of partial onset seizures. |
| Etienne Pigeolet(1), PhilippeJacqmin(2), Maria Laura Sargentini-Maier(1), G. Parker(1) and Armel Stockis(1). Population pharmacokinetics of certolizumab pegol |
| Strougo, A(1), Elassaiss-Schaap, J(2), de Greef, HJMM(2), Drenth, H(1) Mechanism-based model of the effect of co-administration of exogenous testosterone and progestogens on the hypothalamic-pituitary-gonodal axis in men |
| Kim Stuyckens, Stefaan Rossenu, Peter King, Janine Arts, Juan Jose Perez-Ruixo. Modeling Drug Effects and Resistance Development on Tumor Growth Dynamics |
| Stacey Tannenbaum (1), Gene Williams (2), He Sun (3), I. Peter Lee (2), Lawrence Lesko (2), and Robert Temple (2) A Comparison of Fixed Dose-Controlled (FD) versus Pharmacokinetic Modified Dose-Controlled (PKMD) Clinical Study Designs |
| M. Tod (1), B. Blanchet (2), A. Astier (2), A. Hulin (2) Steady-state Equation for the Bicompartmental Model with Gamma Absorption. Application to Mycophenolate PK in Renal Transplant Patients |
| Iñaki F. Trocóniz (1), Raymond Miller (2), Mats O. Karlsson (3) Modelling Overdispersion and Markovian Features in Count Data |
| M. Vernaz-Gris (1), E. Fuseau (1), L. Del Frari (2), V. Brunner (2), P. Hermann (2) Pooled PK analysis of a new CNS drug, in healthy subjects. |
| Sandra Visser(1), Elke Krekels(1), Kristina Ängeby Möller(2), Marie Angesjö(1), Ingemo Sjögren(1) and Odd-Geir Berge(2) Modeling the time-course of the antipyretic effects and prostaglandin inhibition in relation the analgesic effects of naproxen: a compound selection strategy |
| K. Vucicevic(1), B. Miljkovic(1), M. Pokrajac (1), I. Grabnar(2) Population Pharmacokinetic Modelling of Amitriptyline in Depression Patients |
| J.E. Wallin, L. E. Friberg and M. O. Karlsson Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Inter-Occasion Variability and Level and Type of Information Provided |
| Justin J Wilkins (1,2), Radojka M Savic (2), Mats O Karlsson (2), Grant Langdon (1), Helen McIlleron (1), Goonaseelan (Colin) Pillai (3), Peter J Smith (1), Ulrika SH Simonsson (2,4) A flexible approach to modeling variable absorption in the context of repeated dosing: illustrated with rifampicin |
| Benoit You (1,2) , Paul Perrin (1,2), Philippe Paparel (1,2), Gilles Freyer (1,2), Olivier Colomban (1) Brigitte Tranchand (1,3), Pascal Girard (1) Kinetic models of PSA decrease after surgery in prostate tumor diseases as a help for clinician interpretation |
| Stefano Zamuner, Roberto Gomeni Optimal Design to Estimate the Time Varying Receptor Occupancy Relationship in a PET Experiment |
| Anthe S. Zandvliet (1), Jan H.M. Schellens (2,3), William Copalu (4), Jantien Wanders (4), Mats O. Karlsson (5), Jos H. Beijnen (1,2), Alwin D.R. Huitema (1) Phase I study design of indisulam: evaluation and optimization |
| Anthe S. Zandvliet (1), Jan H.M. Schellens (2,3), William Copalu (4), Jantien Wanders (4), Jos H. Beijnen (1,2), Alwin D.R. Huitema (1) Dose individualization of indisulam to reduce the risk of severe myelosuppression |
